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Background: siRNA is a new tool for treatment of diseases such as cancer. However, it cannot be used directly due
to rapid degradation in body fluid and blood stream; therefore, vectors are necessary for protection of siRNA
against RNases and also for its precise delivery to the target cells. Since viral vector causes cancer and immune
response in the host, liposomes are more preferable vectors. Liposome size is an important factor for longer
circulation time. Extrusion minimizes the liposome size; however, it leads to less liposome encapsulation. Moreover,
it changes structure of asymmetric liposomes.
Findings: Here, ethanol treatment is introduced as a method of liposome size optimization that significantly
decreases the liposome size without any effect on liposome encapsulation and its asymmetric structure
formulation. For this, after liposome formation while there is some ether in solution, ethanol was added to fresh
liposomes (25 and 30 percent of total liposomes volume) and liposomes were incubated at room temperature with
mild agitation for 20 minutes. Finally, the extra ethanol and ether were removed by dialysis.
Conclusion: Utilizing this method the liposome size was successfully decreased about 100 nm. The size of
optimized liposomes (200 nm) is quite suitable for in vivo target delivery.
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Discovery of siRNA opened a new window for treatment
of diseases such as cancer. Since siRNA quickly degrades
in blood stream and body fluids [1]; it needs vectors for
protection and proper delivery to the target tissue. There
are two different kinds of vectors for siRNA target de-
livery: viral systems and non-viral systems including
cationic liposomes and polymers [2]. High transfection
efficiency is the most important advantage of viral
systems. However, its usage is limited due to inflamma-
tion and oncogenic potential of viral vectors [3,4]. These
directed researchers toward the non-viral vectors such
as polymers and liposomes, especially cationic liposome
for nucleotide target delivery [5].
Liposomes are exposed to variety of proteins in blood
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distribution, and reproduction in any mediumwhich are able to increase liposomal clearance from the
blood stream [6]. Liposomes removal by liver occurs due
to liposome charge and size which more than fifty
percent of injected liposome is being eliminated from
plasma in less than one hour [7]. Reduction of liposome
size either by optimization of lipid composition or phy-
sical methods of size optimizations such as extrusion
can reduce the rate of liposome removal by liver and in
turn leads to longer circulation time [8]. Extrusion is
currently one of the most common methods of produ-
cing small unilamellar liposomes. However, it decreases
the liposome encapsulation as well [9] and might change
the structure of asymmetric liposomes. This method first
was introduced in 1971 [10]. In order to minimize the
liposome size by extrusion more than ten extrusion
cycles at high trans-membrane pressures are required.
However, even after extrusion all liposomes were not in
the appropriate size [11]. Moreover, extrusion decreases
the liposome encapsulation [9] and structure, in asym-
metric cationic liposomes, which leads to non-specific
cellular uptake of liposome due to changes in outer lipid
formulation.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Ethanol treatment and siRNA encapsulation. Optimized
ALPs with 30% and 25% ethanol and control non-optimized ALPS
(0%) were loaded in adjacent wells in absence and presence of 1%
NP40 to evaluate siRNA encapsulation.
Table 1 Effect of ethanol treatment on liposome size
Size (nm) Zeta potential (mV) Polydispersity (e-1)
Control
Liposome
365.7 ± 41.3 4.97 ± 1.9 2.664 ± 0.15
Treated with
25% Ethanol
255.0 ± 52.2 1.15 ± 2.0 2.242 ± 0.46
Treated with
30% Ethanol
212.5 ± 24.0 −3.25 ± 1.4 2.463 ± 0.19
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zation which can minimize the liposome size without
any effect on encapsulation and structure of asymmetric
liposome formulation.
Material and methods
All lipids for preparing asymmetric liposomes (ALPs) in
this study were purchased from Avanti Polar Lipids, Inc.







ethanolamine (DPPE), and cholesterol (Ch). FITC-labeled
siRNA were obtained from the Bioneer Corporation
(Korea). The dialysis membrane with molecular weight
cut-off values of 10 K Molecular weight cut off (MWCO)
was purchased from Spectrum Laboratories (USA). The
non-small cell lung carcinoma (NSCLC) cells A549, NCI-
H322, NCI-H460, and NIH-3 T3 were obtained from
ATCC (USA). Diethyl ether and ethanol were purchased
from Sigma-Aldrich. All solutions were made up in
Diethylpyrocarbonate (DEPC) water.
Asymmetric liposomes (ALPs) were prepared as previ-
ously explained [12]. Briefly, the inner and outer inverted
micelles were prepared separately in two different test
tubes. The lipid components of the outer layer were
DSPC:DOPE:mPEG-PE:Ch (2:2:1:4, 1.6 μmol total) and
DOTAP (0.13 μmol) only for control liposomes if indi-
cated in text. The inner leaflet was DOTAP:DODAP:
DOPE (4:5:1, 1.5 μmol total). The outer lipid film was
hydrated in a mixture of 200 μl of HEPES buffer Saline
(HBS) (20 mM HEPES and 150 mM sodium chloride;
pH 7.5) and 120 μl ethanol (to be able to dissolve mPEG-
PE); and the inner leaflet was hydrated in 150 μl of sodium
citrate (150 mM, pH 4) containing 100 μg of siRNA.
600 μl and 400 μl diethyl ether was added to the outer
and inner tubes respectively in order to make the outer
and inner inverted micelles. Finally, the inverted micelles
of outer and inner leaflets were mixed, and then diethyl
ether was removed completely by nitrogen gas and dialysis
with 10 K MWCO membrane pore size in HBS.
In order to minimize the liposome size by ethanol
treatment method; immediately after liposome formation
and evaporation of ether by nitrogen gas and before
removing of ether completely by dialysis from the fresh
liposomes, ethanol was added to the tubes containing
fresh liposome to final concentration of 25 and 30 per-
cent of total liposome volume and tubes were inverted
several times to mix it properly and then liposomes were
incubated at room temperature with moderate agitation
for 20 minutes. The extra ethanol which was added forsize optimization was removed by dialysis with 10 K
MWCO membrane pore size in HBS.
Encapsulation efficacy of optimized ALPs after ethanol
treatment was monitored by using 4% agarose gel. The
optimized ALPs were loaded on the 4% agarose gel in
the Tris-borate-EDTA (TBE) buffer with 0.5 μg/ml
ethidium bromide in the absence and presence of 1%
nonidet-P40 (NP40), non-optimized ALPs were used as
control. The siRNA bands were visualized with a gel
documentation system using an ultraviolet transillumi-
nator (Bio-Rad, USA). The siRNA band intensities were
determined by means of densitometric analyses using
the Bio2D program (Vilber Lourmat, France).
Liposome aggregation assay was carried out by mixing
of 30 μl of optimized ALPs with 70 μl fetal bovine
serums (FBS) and mixing of 30 μl of non-optimized
ALPs with 70 FBS as control. Then samples were incu-
bated at 37°C for 8 hours. Turbidity of samples was
measured using 550 nm with a multi label plate reader
(PerkinEl-mer VICTOR 3 1420, USA).
Cellular uptake was done to check the stability of asym-
metric structure of optimized ALPs after size treatment.
The NSCLC cells (A549, NCI-H322 and NCI-H460) were
cultured in micro-slide eight-well microscopy chambers
(ibidi 8 well plates, Germany) in DMEM-FBS. Then cells
were treated with optimized ALPs (containing FITS-
siRNA) and control liposome which was prepared by
adding of DOTAP (0.13 μmol) to the outer layer. After
1 day of incubation, the cells were rinsed twice in PBS and
fixed with 4% formaldehyde in PBS at room temperature
for 10 min. The cellular uptake of FITC-siRNA was moni-
tored with a confocal microscope.
Figure 2 Liposome aggregation assay (P < 0.05).
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The effect of ethanol treatment on ALPs siRNA en-
capsulation was evaluated by gel electrophoresis assay.
Optimized liposomes showed more than 90% siRNA
encapsulation, comparable with control non-optimized
ALPs (Figure 1), which means ethanol does not have any
effect on liposome encapsulation. However, the size of opti-
mized ALPs dramatically was decreased from 365.7 nm to
225 and 212 nm depending on the ethanol concentration
(Table 1). The optimized ALPs size was much smaller after
ethanol treatment.
In order to evaluate the effect of ethanol treatment on
the structure of outer layer of optimized liposome which
is important in liposome interaction with serum proteins
and elimination of liposomes from the blood, aggrega-
tion assay and cellular uptake study were performed.
Optimized liposome with ethanol, the same as control
non-optimized ALPs, did not have any significant change
in turbidity during 8 hours incubation in presence of FBS
(Figure 2), which means the optimized ALPs has no inter-
action with the serum protein, quite similar to control no-
optimized ALPs.
Treatment of NSCLC cells with optimized ALPs and
non-optimized-ALPs containing DOTAP in outer layerFigure 3 Cellular uptake of optimized ALPs. Control non-optimized ALP
(down). However, optimized liposome had no cellular uptakes which certifas control were done in order to evaluate the possible
replacement of cationic lipids of inner layer, DOTAP,
with any of lipids in outer layer which can change the
structure and properties of ALPs after size optimization
with ethanol. As the results show, the optimized lipo-
somes has no penetration in none of the NSCLC cells
(Figure 3, up), similar to non-optimized ALPs [12]; how-
ever the control liposomes containing DOTAP in outer
layer penetrated in all of the cells (Figure 3, down).
Discussion
Asymmetric liposomes using cationic lipid presents 90%
siRNA encapsulation [12]. The asymmetric structure of
liposomes eliminates non-specific liposomal cellular
uptake arising from the positive charge of cationic lipids
[12]. Cationic lipids are essential and inevitable in
liposome formulation for higher siRNA encapsulation
whereas the asymmetric structure is important for elimi-
nating of non-specific targeting. Therefore, it is important
to optimize and minimize the asymmetric liposome size
by a method which has no effect on the asymmetric struc-
ture of liposomes and moreover makes it in appropriate
size for longer circulation time. Here, we introduce
ethanol treatment as a proper method of liposome size
optimization that reduces the liposome size without any
specific effect on the ALPs structure and properties.
Treatment of liposomes by ethanol to final concentra-
tion of 25 and 30 percent remarkably decreases the
liposome size, about 100 nm from 365.7 nm to 225 nm or
212.5, and zeta potential, from 4.97 ± 1.9 to −3.25 ± 1.4,
depending on the ethanol concentration (Table 1); how-
ever, it did not decrease the siRNA encapsulation
(Figure 1). It is critical to add ethanol before complete
ether removal by dialysis since after ether removal; ethanol
treatment decreases the liposome encapsulation to 65–70
percent (Data not shown).
One of the major reasons of liposomes clearance from
the blood circulation is liposome charge. Positive charges containing DOTAP in outer layer showed a high cellular uptake
y might not be DOTAP in outer leaflet (up).
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elimination from blood circulation, due to interaction of
liposomes with serum proteins, but also it increases
non-specific liposome removal by cell. However, asym-
metric cationic liposomes having positive charge only in
inner layer showed high siRNA encapsulation and no
non-specific cellular uptake [12]. Any change in asym-
metric structure of optimized ALPs after ethanol treat-
ment might leads to changes in liposome surface charge
and in turn leads to higher interaction of optimized
ALPs with the serum proteins. However, turbidity of
optimized ALPs did not changed during 8 hours incuba-
tion similar as turbidity of control non-optimized ALPs
(Figure 2). It proves that the ethanol treatment might
not have any significant effect on the liposome structure
so that both optimized and control ALPs show the same
results.
Cellular uptake study was done with control liposomes
containing DOTAP in outer layer (0.13 μmol, equal with
20 percent of total DOTAP in inner layer) to induce
positive charge on the liposome surface. The results of
cellular uptake study (Figure 3) showed no cellular uptake
only for optimized liposome. This was another proof that
there might not be any change in the asymmetric
liposomes structure due to ethanol treatment, since the
replacement of inner layer DOTAP with any lipids of
outer layer could induce positive charge on the liposome
surface and increase cellular uptake consequently.
Conclusion
In conclusion, ethanol treatment is a simple and an
appropriate method of liposome size optimization which
decreases the liposome size effectively without any effect
on siRNA encapsulation and properties.
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